Request a USG CoronaWatch Meeting
Currently, our attention is limited to COVID-19 response; as such, we are not reviewing meeting requests not related to COVID-19. We ask you to refrain from submitting requests for other products and technologies at this time.
The U.S. government is providing a portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders.
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.
At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.
Ideal technologies and products would (but are not required to) be:
- - Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities
- - Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
- - Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Would you like to meet with a federal agency regarding a product that you are developing for COVID-19?
NOTE: BARDA Coronawatch/Techwatch meeting requests are for market research purposes only and are not considered submissions for potential funding. If a requestor would like to be considered for funding through BARDA they would need to apply through the Broad Agency Announcement or the EZ-Broad Agency Announcement.
If you are interested in requesting a CoronaWatch meeting, please Register for an account and Login, or if you have an account Login to submit some basic product information. Also, Login to view or update existing submissions. Please do not submit multiple requests for the same product or technology.
We will evaluate your request and route it to the most appropriate resource within the federal government. In some instances, it is not necessary or appropriate for a federal agency representative to meet with companies regarding their products. In the event that a federal agency representative is unable to meet with you, we will provide you with that information in a timely manner.
What is CoronaWatch/TechWatch
To enable a rapid-response to the COVID-19 outbreak, BARDA has repurposed our existing TechWatch program to focus on COVID-19 medical countermeasures. These CoronaWatch submissions and meetings aim to give innovators and innovative companies a government-wide platform to discuss their ideas with U.S. government experts, and seek partnership opportunities with a wide range of potential federal partners.
If you or your company are developing a medical countermeasure, platform technology, or other innovative product in our mission space, you can engage BARDA and other PHEMCE partner agencies to gain technical feedback on what is presented and strategic input as to its relevance for our mission at a CoronaWatch/TechWatch meeting. This TechWatch web portal is serving as the single point of entry for interested entities submitting market research and meeting requests for the U.S. government COVID-19 medical countermeasures task force. At this time, we are not seeking submissions from medical countermeasure developers that do not pertain to COVID-19.
CoronaWatch meetings will be held via interactive webinar only, and we will be able to interactively display slides and manuscripts received electronically. Though not required, meetings generally have two phases. The first is a presentation from the meeting requestor to government personnel, which is informal and highly interactive. The second phase is a discussion among the participants. Scientific subject matter experts from the PHEMCE partner agencies (including BARDA) and contracting officers will attend. Additional details will be provided at the time a meeting is scheduled.
TechWatch Meeting Benefits• Gain visibility for your solution
• Receive feedback from USG experts
• Hear techniques and strategies for addressing technical and regulatory challenges
• Get insight on how your solution could fit within the Government
• Better prepare you for a formal proposal submission
Making the Most of Your TechWatch
Note: Entities with a White Paper or proposal currently under review for any ASPR solicitation are not eligible to schedule a TechWatch meeting related to that submission given that it invokes a period of silence during the review process. If you have concerns regarding your eligibility, please raise them with our TechWatch team.
- • All submissions are voluntary and are for information only. However, submitting complete information may facilitate request routing.
- • Review submitted request by Logging in and selecting View on the My Requests page.
- • If you have additional questions about the TechWatch program, please contact us: TechWatchInbox@hhs.gov.
Background on the TechWatch Program
The Pandemic and All-Hazards Preparedness Act (2006) (PDF - 248 KB) calls for BARDA to reach out to stakeholders in industry, academia, government, and other institutions to identify new ideas and resources for accomplishing its medical countermeasure mission. This has been reaffirmed in PAHPRA, PAHPAIA and the 21st Century Cures Act. BARDA therefore maintains an active outreach and scouting function with three main components: constant monitoring of announcements, publications and meetings relevant to the field; BARDA’s annual Industry Day conference; and the BARDA TechWatch program.
The goals of BARDA’s TechWatch program are outreach to stakeholders across the medical countermeasure enterprise and engagement with them through meetings to discuss their product candidates and technologies and their possible alignment with BARDA’s mission. In order to meet this goal, BARDA developed a web-based infrastructure for organizing such meetings. Organizations can initiate the process of arranging a meeting by providing information and requesting BARDA TechWatch meetings via an online form, either at BARDA’s invitation or on their own initiative. BARDA TechWatch meetings typically are one-hour, seminar-style meetings with appropriate Program and Technical staff, either virtually or at BARDA’s D.C. offices. BARDA TechWatch meetings are informational in nature and not part of the contracting process, but the information exchanged may inform BARDA strategies and the engagement may help organizations better understand BARDA’s priorities and be more responsive to its solicitations.
The BARDA TechWatch program is very popular, and has been enhanced significantly in recent years. Since the inception of the program in 2007, over 1,000 BARDA TechWatch meetings have been held and interest in the program has steadily grown. On average, approximately 200 meeting requests are received each year and about 125 onsite are conducted. Additionally, BARDA holds more than 50 telephonic TechWatches annually. The ongoing success of the BARDA TechWatch Program will ensure that BARDA meets its statutory directive to engage fully with its stakeholders. BARDA TechWatch continues to be a key piece in BARDA’s engagement function during routine and emergency operations, and it will remain integral to the success of BARDA’s mission